Cingulate therapeutics ipo
WebOct 26, 2024 · KANSAS CITY, Kan., Oct. 26, 2024 /PRNewswire/ -- Cingulate Therapeutics, a privately-held, clinical-stage, biopharmaceutical company focused on the development of innovative new products for... WebCING Complete Cingulate Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Cingulate therapeutics ipo
Did you know?
WebApr 8, 2024 · Open an account. Provide your personal information and sign up. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account. Search for the stock name – CING. Search for the stock by name or ticker symbol. Buy the stock. Place your order. WebFounded Date Dec 1, 2012. Founders Craig Gilgallon, Matthew Brams, Raul Silva, Shane J Schaffer. Operating Status Active. Last Funding Type Venture - Series Unknown. Stock Symbol NASDAQ:CING. Company …
WebApr 10, 2024 · Analyst Forecast. According to 10 analysts, the average rating for CING stock is "Buy." The 12-month stock price forecast is $5.99, which is an increase of 508.12% … WebOct 12, 2024 · Three healthcare IPOs are set for pricing Thursday night, Oct. 14, to start trading on Friday the 15 th: Cingulate Inc. (CING proposed), a clinical biopharma deal …
WebMar 10, 2024 · The increase from 2024 to 2024 was related to the recognition of $4.6 million of R&D expense for a one-time, noncash compensation charge in the third quarter of 2024 due to the exchange of Profits Interest Units (PIUs) in Cingulate Therapeutics LLC for common stock of Cingulate Inc. prior to the IPO, which was based on the fair value of … WebSep 30, 2024 · Cingulate (NASDAQ: CING ), the biotech company that is developing formulations of stimulant drugs for ADHD, is making its public debut soon. Here are 7 key things to know about the upcoming CING...
WebKANSAS CITY, Kan., Dec. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (Cingulate or the Company), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR ...
WebOct 8, 2024 · Cognition Therapeutics priced its IPO at the mid-point. Cognition Therapeutics raised $45.2 million by offering 3.8 million shares in the IPO at $12 each. Previously, the company planned to offer ... imperial place red deerWebCingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is being … imperial place maxwell road borehamwoodWebCingulate upsized its IPO at pricing on Dec. 7, 2024, to 4.17 million shares, up from 3.57 ... imperial plaid csgoWebCingulate Therapeutics, LLC (CTx) is a privately held, clinical-stage biopharmaceutical company focused on the development of innovative new products utilizing the Company’s disruptive, proprietary Precision Timed Release™ (PTR™) drug delivery platfo... imperial place owensboro kyWebDec 8, 2024 · Use the CB Insights Platform to explore Cingulate Therapeutics's full profile. Cingulate Therapeutics - Products, Competitors, Financials, Employees, Headquarters Locations Technology Vendors imperial planets 40kWebSep 24, 2024 · Cingulate ( NASDAQ: CING) has filed to raise $57.5 million in an IPO of its common stock, according to an S-1 registration statement. The firm is developing Precision Timed Release [PTR] drug ... litco parking garage resurfacingWebOct 13, 2024 · Comments by IPO Boutique, including our e-mail alerts and advisories are the observations of the staff of IPO Boutique. They are not intended to be absolute recommendations to buy, hold or sell securities but carefully chosen advisory information, or an endorsement of any specific security or trading strategy. imperial planets